Terms: = Leukemia AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Prognosis
71 results:
1. cxcr4 overexpression in chronic lymphocytic leukemia associates with poorer prognosis: A prospective, single-center, observational study.
Xue X; Wen Z; Zhang X; Yang Y; Li Y; Liao R; Zheng Q; Fu Y; Liu Y; Liao H
Genes Immun; 2024 Apr; 25(2):117-123. PubMed ID: 38366101
[TBL] [Abstract] [Full Text] [Related]
2. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
3. Nuclear Medicine Application of Pentixafor/Pentixather Targeting cxcr4 for Imaging and Therapy in Related Disease.
Chen Z; Xue Q; Yao S
Mini Rev Med Chem; 2023; 23(7):787-803. PubMed ID: 36529918
[TBL] [Abstract] [Full Text] [Related]
4. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
[TBL] [Abstract] [Full Text] [Related]
5. Nanomicelles co-loading cxcr4 antagonist and doxorubicin combat the refractory acute myeloid leukemia.
Zhang M; Ge Y; Xu S; Fang X; Meng J; Yu L; Wang C; Liu J; Wen T; Yang Y; Wang C; Xu H
Pharmacol Res; 2022 Nov; 185():106503. PubMed ID: 36241000
[TBL] [Abstract] [Full Text] [Related]
6. Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression.
Stetson LC; Balasubramanian D; Ribeiro SP; Stefan T; Gupta K; Xu X; Fourati S; Roe A; Jackson Z; Schauner R; Sharma A; Tamilselvan B; Li S; de Lima M; Hwang TH; Balderas R; Saunthararajah Y; Maciejewski J; LaFramboise T; Barnholtz-Sloan JS; Sekaly RP; Wald DN
Leukemia; 2021 Oct; 35(10):2799-2812. PubMed ID: 34244611
[TBL] [Abstract] [Full Text] [Related]
7. cxcr4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients.
El-Sherif WT; Salah El-Din EM; Aly MM; Said MG; Nigm DA
Egypt J Immunol; 2021 Jul; 28(3):114-126. PubMed ID: 34185460
[TBL] [Abstract] [Full Text] [Related]
8. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
Yu X; Munoz-Sagredo L; Streule K; Muschong P; Bayer E; Walter RJ; Gutjahr JC; Greil R; Concha ML; Müller-Tidow C; Hartmann TN; Orian-Rousseau V
Blood; 2021 Sep; 138(12):1067-1080. PubMed ID: 34115113
[TBL] [Abstract] [Full Text] [Related]
9. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing cxcr4.
Pallarès V; Núñez Y; Sánchez-García L; Falgàs A; Serna N; Unzueta U; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Control Release; 2021 Jul; 335():117-129. PubMed ID: 34004204
[TBL] [Abstract] [Full Text] [Related]
10. Association of SDF-1 Gene Polymorphism with Increased Risk of Acute Myeloid leukemia Patients.
Aladle DAAM; Ghannam MA; El-Ashwah S; Ghobrial FEI; Mortada MI
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1035-1043. PubMed ID: 33906294
[TBL] [Abstract] [Full Text] [Related]
11. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
[TBL] [Abstract] [Full Text] [Related]
12. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards cxcr4
Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
[TBL] [Abstract] [Full Text] [Related]
13. Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.
Klintman J; Appleby N; Stamatopoulos B; Ridout K; Eyre TA; Robbe P; Pascua LL; Knight SJL; Dreau H; Cabes M; Popitsch N; Ehinger M; Martín-Subero JI; Campo E; Månsson R; Rossi D; Taylor JC; Vavoulis DV; Schuh A
Blood; 2021 May; 137(20):2800-2816. PubMed ID: 33206936
[TBL] [Abstract] [Full Text] [Related]
14. High CXCR3 on Leukemic Cells Distinguishes
Manukyan G; Papajik T; Mikulkova Z; Urbanova R; Kraiczova VS; Savara J; Kudelka M; Turcsanyi P; Kriegova E
J Immunol Res; 2020; 2020():7084268. PubMed ID: 32802894
[TBL] [Abstract] [Full Text] [Related]
15. De Novo CD5
Xu Y; Sun W; Li F
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e782-e790. PubMed ID: 32694049
[TBL] [Abstract] [Full Text] [Related]
16. SDF-1α Reduces Human Natural Killer Cell Cytotoxicity against Chronic Myelogenous leukemia K562 Cells.
Mardomi A; Hossein-Nataj H; Jafari N; Mohammadi N; Abediankenari S
Iran J Allergy Asthma Immunol; 2019 Oct; 18(5):493-500. PubMed ID: 32245293
[TBL] [Abstract] [Full Text] [Related]
17. Association of cxcr4 Expression and Clinical Outcome in Different Subsets of De Novo Acute Myeloid leukemia Patients.
Rady AS; Badawy RH; Gamal BME; Darwish AD; Aziz RSA; Gammal ME; Goweda RA
Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162869
[TBL] [Abstract] [Full Text] [Related]
18. Transmembrane adaptor protein WBP1L regulates cxcr4 signalling and murine haematopoiesis.
Borna S; Drobek A; Kralova J; Glatzova D; Splichalova I; Fabisik M; Pokorna J; Skopcova T; Angelisova P; Kanderova V; Starkova J; Stanek P; Matveichuk OV; Pavliuchenko N; Kwiatkowska K; Protty MB; Tomlinson MG; Alberich-Jorda M; Korinek V; Brdicka T
J Cell Mol Med; 2020 Jan; 24(2):1980-1992. PubMed ID: 31845480
[TBL] [Abstract] [Full Text] [Related]
19. Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells.
López-Guerra M; Xargay-Torrent S; Fuentes P; Roldán J; González-Farré B; Rosich L; Silkenstedt E; García-León MJ; Lee-Vergés E; Giménez N; Giró A; Aymerich M; Villamor N; Delgado J; López-Guillermo A; Puente XS; Campo E; Toribio ML; Colomer D
Oncogene; 2020 Feb; 39(6):1185-1197. PubMed ID: 31616059
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic significance of cxcr4 expression in acute myeloid leukemia.
Du W; Lu C; Zhu X; Hu D; Chen X; Li J; Liu W; Zhu J; He Y; Yao J
Cancer Med; 2019 Nov; 8(15):6595-6603. PubMed ID: 31518054
[TBL] [Abstract] [Full Text] [Related]
[Next]
